Cyclic nucleotide phosphodiesterase 3 signaling complexes.

@article{Ahmad2012CyclicNP,
  title={Cyclic nucleotide phosphodiesterase 3 signaling complexes.},
  author={Faiyaz Ahmad and Eva Degerman and Vincent C. Manganiello},
  journal={Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme},
  year={2012},
  volume={44 10},
  pages={
          776-85
        }
}
The superfamily of cyclic nucleotide phosphodiesterases is comprised of 11 gene families. By hydrolyzing cAMP and cGMP, PDEs are major determinants in the regulation of intracellular concentrations of cyclic nucleotides and cyclic nucleotide-dependent signaling pathways. Two PDE3 subfamilies, PDE3A and PDE3B, have been described. PDE3A and PDE3B hydrolyze cAMP and cGMP with high affinity in a mutually competitive manner and are regulators of a number of important cAMP- and cGMP-mediated… 
Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
TLDR
Future paths to novel drug discovery include the crystal structure-based design approach, which has resulted in generation of more effective family-selective inhibitors, as well as burgeoning development of strategies to alter compartmentalized cyclic nucleotide signaling pathways by selectively targeting individual PDEs and their signalosome partners.
Clinical and molecular genetics of the phosphodiesterases (PDEs).
TLDR
How PDEs affect cAMP and cGMP signaling in health and disease, and what pharmacological exploitations of Pdes may be useful in modulating cyclic nucleotide signaling in a way that prevents or treats certain human diseases are reviewed.
Functional characterisation of phosphodiesterase 4D7 in prostate cancer
TLDR
Significant changes in cAMP signalling during PC progression are found by studying the expression of cAMP PDE isoforms, with the aim of identifying a novel PC biomarker, as the current standard biomarker (PSA) is not disease-specific and leads to much over-diagnosis and over-treatment of otherwise non-life threatening prostate tumours.
Inhibitors of phosphodiesterase as cancer therapeutics.
Development of Phosphodiesterase–Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity
TLDR
A developed fluorescence polarization assay was adapted to identify inhibitors that block cyclic nucleotide pockets in PDE–PK complexes in one mode and disrupt protein-protein interactions between PDEs and PKs in a second mode, thereby offering greater specificity.
Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.
TLDR
These data identify a new effect of PDE5 inhibitors on the modulation of cardiomyocyte response to adrenergic stimulation via Pde5-PDE2-mediated cross-talk and support a compartmentalization of the cGMP-modulated pool of cAMP.
Cyclic AMP Signaling
TLDR
The major mechanisms underlying cAMP-mediated vasodilatation include the activation of potassium channels, theactivation of myosin light chain phosphatase, and the inhibition of RhoA/Rho kinase signaling.
Newly synthesized cAMP is integrated at a membrane protein complex signalosome to ensure receptor response specificity
TLDR
In hepatocyte plasma membranes, two functional and independent cAMP‐responsive signaling protein macrocomplexes that produce, use, degrade, and regulate their own nondiffusible (sequestered) cAMP pool to achieve their specific responses.
cUMP hydrolysis by PDE3B
TLDR
The enzyme kinetics of PDE3B-mediated cUMP hydrolysis was characterized, the Pde3B binding mode of cUMP was determined, and cUMP Hydrolysis in adipocyte preparations was analyzed to analyze cUMP-hydrolytic activity in adipocytes preparations.
...
1
2
3
...

References

SHOWING 1-10 OF 97 REFERENCES
cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling.
TLDR
How cardiomyocytes and vascular smooth muscle cells selectively vary both the expression and the catalytic activities of PDE4 isoforms to regulate their various functions are described and how altered regulation of these processes can influence the development of cardiovascular pathologies, such as heart failure, as well as various vasculopathies.
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
TLDR
Some of the major concepts related to the understanding of PDE function and regulation are reviewed including the structure of catalytic and regulatory domains and arrangement in holoenzymes, the nature and function of negative and positive feedback circuits that have been conserved in PDEs from prokaryotes to human, and the emerging association of mutant PDE alleles with inherited diseases.
Overview of PDEs and Their Regulation
TLDR
Multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiological homeostasis.
Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)*
TLDR
This review emphasizes the PDE3 family, including structure-function information and regulation of the adipocyte PDE2, which plays a key role in the antilipolytic action of insulin, and other aspects of different PDE families will be discussed.
Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3)
TLDR
Subcellular localization of cyclic nucleotide phosphodiesterases (PDEs) may be important in compartmentalization of cAMP/cGMP signaling responses and some portion of the N-terminal hydrophobicdomain in region 1 plus a second domain in region 2 are important for efficient membrane association/targeting of PDE3.
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
TLDR
Basic biochemical properties, cellular regulation, expression patterns, and physiological functions of the different PDE isoforms will be discussed and how these properties relate to the current and future development of PDE inhibitors as pharmacological agents is especially considered.
Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium*
TLDR
The findings indicate that the contribution of PDE3 isoforms to the regulation of cAMP hydrolysis in intracellular compartments of human myocardium and the effects of Pde3 inhibition in these compartments are highly dependent on intrACEllular [Ca2+] and [cAMP], which are lower in failing hearts than in normal hearts.
Phosphodiesterase 4D and heart failure: a cautionary tale
TLDR
Pharmacological PDE inhibition increases intracellular cAMP concentrations and augments excitation–contraction coupling in heart failure, however, chronic PDE inhibitor treatment causes severe cardiac side effects and increases mortality.
Implications of PDE4 structure on inhibitor selectivity across PDE families
  • H. Ke
  • Biology, Chemistry
    International Journal of Impotence Research
  • 2004
TLDR
Crystal structure analysis of PDE4's catalytic domain identifies two metal-binding sites: a high-Affinity site and a low-affinity site, which probably bind zinc and magnesium and suggest the importance of these amino acids in catalysis.
Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
TLDR
These structures explain the dual cAMP/cGMP binding capabilities of PDE3, provide the molecular basis for inhibitor specificity, and can supply a valid platform for the design of improved compounds.
...
1
2
3
4
5
...